Nsonaazụ mgbawa nke CD7-Ezubere iche maka CAR-T ọgwụgwọ maka T-ALL na T-LBL

Nnwale a na-eme n'ụlọ ọgwụ na nso nso a egosila ọganihu dị ịrịba ama na ọgwụgwọ T-cell nnukwu lymphoblastic leukemia (T-ALL) na T-cell lymphoblastic lymphoma (T-LBL) na-eji CD7-ezubere iche chimeric antigen receptor (CAR) T cell therapy. . Ọmụmụ ihe a, nke otu sitere na ụlọ ọgwụ Hebei Yanda Lu Daopei na Lu Daopei Institute of Hematology mere, gụnyere ndị ọrịa 60 bụ ndị natara otu mkpụrụ ọgwụ mgbochi CD7 CAR (NS7CAR) T sel.

Nsonaazụ ikpe a na-agba ume nke ukwuu. Site na ụbọchị 28, 94.4% nke ndị ọrịa nwetara mgbaghara zuru oke (CR) na ụmị ọkpụkpụ. Na mgbakwunye, n'ime ndị ọrịa 32 nwere ọrịa extramedullary, 78.1% gosipụtara nzaghachi dị mma, yana 56.3% na-enweta mgbaghara zuru oke yana 21.9% na-enweta mgbaghara akụkụ. Afọ abụọ n'ozuzu nlanarị na ọnụ ọgụgụ nlanarị na-enweghị ọganihu bụ 63.5% na 53.7%, n'otu n'otu.

Usoro ọgwụgwọ ọhụrụ a bụ ihe kwesịrị ịrịba ama maka profaịlụ nchekwa ya nwere ike ijikwa, yana ọrịa ntọhapụ cytokine na-eme na 91.7% nke ndị ọrịa (ọtụtụ ọkwa 1/2), na neurotoxicity hụrụ na 5% nke ikpe. Ọzọkwa, ọmụmụ ahụ chọpụtara na ndị ọrịa na-aga n'ihu na ntughari nchikota mgbe ha nwetasịrị CR nwere ọnụ ọgụgụ nlanarị na-enweghị ọganihu dị elu karịa ndị na-emeghị.

Ụlọ ọrụ anyị na-enyochakwa ike nke CD7 CAR-T cell therapy na ngwaahịa anyị, na-achọ itinye aka na ọganihu nke ọgwụgwọ maka ọrịa T-cell.

Nchọpụta ndị a na-emesi ike ike nke CD7-ezubere iche maka ọgwụgwọ cell CAR-T na-enye olileanya ọhụrụ maka ndị ọrịa nwere T-ALL na T-LBL na-atụgharị ma ọ bụ na-alaghachi azụ, na-akara akara dị ịrịba ama na agha na-aga n'ihu megide ọrịa ndị a siri ike.